Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)
OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach
"OZEM offers investors a unique opportunity to efficiently access the companies leading the charge against the global obesity epidemic," said
The obesity treatment market is set for explosive growth.
The Roundhill GLP-1 & Weight Loss ETF (OZEM) is an actively-managed ETF that is designed to provide exposure to a global portfolio of companies involved in developing weight loss therapeutics.
The fund's top holdings include:
HOLDINGS |
% WEIGHTING |
Eli Lilly & Co |
20.16 % |
Novo Nordisk A/S |
19.90 % |
Innovent Biologics Inc |
4.59 % |
Zealand Pharma A/S |
4.57 % |
Chugai Pharmaceutical Co Ltd |
4.47 % |
Amgen Inc |
4.24 % |
|
4.19 % |
Viking Therapeutics Inc |
3.50 % |
Terns Pharmaceuticals Inc |
3.41 % |
|
3.24 % |
Holdings are subject to change. Data as of 5/20/24.
1 WHO,
About Roundhill Investments
Founded in 2018, Roundhill Investments is an
Investors should consider the investment objectives, risk, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about Roundhill ETFs please call 1-855-561-5728 or visit the website at www.roundhillinvestments.com/etf/OZEM. Read the prospectus or summary prospectus carefully before investing.
Health Care Companies Risk. Health care companies, such as companies providing medical and healthcare goods and services, companies engaged in manufacturing medical equipment, supplies and pharmaceuticals, as well as operating health care facilities and the provision of managed health care, may be affected by government regulations and government health care programs, increases or decreases in the cost of medical products and services and product liability claims, among other factors. Many health care companies are heavily dependent on patent protection, and the expiration of a company's patent may adversely affect that company's profitability. Health care companies are also subject to competitive forces that may result in price discounting, may be thinly capitalized and susceptible to product obsolescence.
Pharmaceutical Companies Risk. The Fund may have significant exposure to pharmaceutical companies in connection with its investments in GLP-1 & Weight Loss Companies.
Pharmaceuticals companies may be affected by industry competition, dependency on a limited number of products, obsolescence of products, government approvals and regulations, loss or impairment of intellectual property rights and litigation regarding product liability. Pharmaceutical are subject to competitive forces that may make it difficult to raise prices of their products and may result in price discounting. The profitability of some pharmaceuticals companies may be dependent on a relatively limited number of products. The research and development costs required to bring a new product to market are substantial with no guarantee that the product will ever become profitable. Many new products are subject to gaining the approval of the
Biotechnology Companies Risk. The Fund may have significant exposure to biotechnology companies in connection with its investments in GLP-1 & Weight Loss Companies. Biotechnology companies invest heavily in research and development which may not necessarily lead to commercially successful products. Biotechnology companies are subject to increased governmental regulation which may delay or inhibit the release of new products. The effects of high development costs and increased regulation may be exacerbated by a company's inability to raise prices to cover costs because of managed care pressure or price controls. Many biotechnology companies are dependent upon their ability to use and enforce intellectual property rights and patents. Any impairment of such rights may have adverse financial consequences. Biotechnology stocks, especially those issued by smaller, less-seasoned companies, tend to be more volatile than the overall market. Biotechnology companies can also be significantly affected by technological change and obsolescence, product liability lawsuits and consequential high insurance costs.
Concentration Risk. The Fund is concentrated in the industry or group of industries comprising the health care sector. The Fund may be susceptible to an increased risk of loss, including losses due to adverse events that affect the Fund's investments more than the market as a whole, to the extent that the Fund's investments are concentrated in the securities and/or other assets of a particular issuer or issuers, country, group of countries, region, market, industry, group of industries, sector, market segment or asset class.
New Fund Risk. The Fund is a recently organized investment company with a limited operating history. As a result, prospective investors have a limited track record or history on which to base their investment decision.
View original content to download multimedia:https://www.prnewswire.com/news-releases/roundhill-investments-launches-glp-1--weight-loss-etf-ozem-302150664.html
SOURCE Roundhill Investments